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Abstract
Acute kidney injury (AKI) is a serious public health issue, with an increasing incidence 
and significant associated deleterious effects. Several studies have reported the conse-
quences of AKI, including prolonged hospital stay, increased healthcare costs, morbidity, 
and mortality. Many factors are known to affect AKI development. Kidney is exposed 
to a larger proportion and a higher concentration of drugs and toxins than other organs 
through the secretion of ionic drugs by tubular organic ion transporters across the lumi-
nal membranes of renal tubular epithelial cells and through reabsorption of filtered tox-
ins into the lumen of the tubule; these cells are at a greater risk for injury. This section 
gives an overview of AKI including the definition, causes, and prognosis.
Keywords: acute kidney injury, drug, prognosis
1. Introduction
1.1. AKI definition
Acute kidney injury (AKI) results in an acute and usually transient decrease in renal function. 
AKI is defined as any of the following (not graded): (1) an increase in serum creatinine (SCr) by 
≥0.3 mg/dl (≥26.5 mol/l) within 48 h, or (2) an increase in SCr to ≥1.5 times baseline that is known 
or presumed to have occurred within the prior 7 days, or (3) urine volume < 0.5 ml/kg/h for 6 h.
1.2. Clinical stratification of AKI
The RIFLE (Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss 
of kidney function and End-stage kidney disease) classification was proposed as a diagnostic 
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criterion of acute renal failure (ARF) in order to ameliorate the morbidity and mortality of 
ARF (Table 1) [1–3]. Under this proposal, AKI has instead been proposed to be called ARF. In 
addition, the AKI Network (AKIN) was formed around the attendees of a critical care and 
kidney-related conference; the revised version of the RIFLE classification by the AKIN was 
proposed as the diagnostic criterion of AKI (Table 2) [4] and the Kidney Disease Improving 
Global Outcomes (KDIGO) were used for the diagnosis of AKI, where the clinical conditions 
are elevated serum creatinine level and a decreased urine output within 48 h (Table 3) [5].
SCr, serum creatinine; ESKD, end-stage kidney disease.
An abrupt (within 48 h) reduction in kidney function is currently defined as an absolute 
increase in serum creatinine of more than or equal to 0.3 mg/dl (≥26.4 μmol/l), a percentage 
increase in serum creatinine of more than or equal to 50% (1.5-fold from baseline), or a reduc-
tion in urine output (documented oliguria of less than 0.5 ml/kg per hour for more than 6 h). 
AKI is diagnosed if one of the definitions in 1–3 is met. If a diagnosis is made based solely on 
urine output, this diagnostic criterion is used under the condition that body fluid volume is 
properly corrected and urinary tract obstruction or readily reversible oliguria are excluded. 
SCr, serum creatinine.
Stage SCr Urine output
Stage 1 Increase in SCr of more than or equal to 0.3 mg/dl or increase to more 
than or equal to 150–200% (1.5- to 2-fold) from baseline
Less than 0.5 ml/kg/h for more 
than 6 h
Stage 2 Increase in SCr to more than 200–300% (>2- to 3-fold) from baseline Less than 0.5 ml/kg/h for more 
than 12 h
Stage 3 Increase in SCr to more than 300% (>3-fold) from baseline or SCr 
of more than or equal to 4.0 mg/dl with an acute increase of at least 
0.5 mg/dl
Less than 0.3 ml/kg/h for 24 h or 
anuria for 12 h
Table 2. AKIN classification.
Glomerular filtration rate (GFR) Urine output
Risk SCr more than 1.5 times or GFR decrease >25% Less than 0.5 ml/kg/h for more than 6 h
Injury SCr more than 2.0 times or GFR decrease >50% Less than 0.5 ml/kg/h for more than 12 h
Failure SCr more than 3.0 times, or GFR decrease >75%, or SCr 
≥0.5 mg/dl with acute elevation SCr ≥4 mg/dl
Less than 0.3 ml/kg/h for more than 24 h or 
anuria for more than 12 h
Loss Continued ARF (complete loss of kidney function) for 
more than 4 weeks
Continued ARF (complete loss of kidney 
function) for more than 4 weeks
ESKD End-stage kidney disease (dialysis dependency for more 
than 3 months)
End-stage kidney disease (dialysis dependency 
for more than 3 months)
Table 1. RIFLE classification.
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1.3. Classification of AKI
AKI is classified roughly into prerenal, renal, and postrenal according to the site of onset [6]. 
Prerenal refers to cases of a decreased blood flow to the kidney as a result of systemic illness. 
Renal refers to cases with roots in the kidney. Postrenal refers to cases caused by issues in the 
lower urinary tract (urinary duct, bladder, or urethral tube).
2. Drug-induced AKI
2.1. Definition
Drug-induced kidney injury (DKI) is a general term for newly occurring kidney injury or 
kidney injury that has been exacerbated by the drugs administered for diagnosis and treat-
ment. Furthermore, DKI can be classified as follows: toxic kidney injury, acute interstitial 
nephritis by allergy mechanism (hypersensitivity kidney injury), drug-induced indirect toxic-
ity through electrolyte abnormality and blood flow decrease, drug-induced crystal formation, 
and urinary tract obstruction kidney injury for calculus formation.
2.2. Etiology
Because primary urine, largely filtered by the glomeruli, is reabsorbed in the proximal tubules, 
drugs and metabolites are easily accumulated in high concentrations in the kidney. For this 
reason, the kidney is susceptible to drug-induced injury. Because primary urine becomes 
concentrated in the proximal tubules after primary urine is filtered from the glomeruli, 
tubular necrosis through direct toxicity occurs with an increased frequency in a dose-related 
fashion. Drug-induced kidney injury is defined by a new-onset disorder of the kidney or a 
further exacerbation of the existing dysfunction of the kidney by the administration of drugs. 
Furthermore, when patients have risk factors, such as older age (elderly), compromised 
renal function (chronic kidney failure), dehydration, frequent administration of drugs, and 
baseline disease (diabetes mellitus or myeloma), disorder of the kidney tends to take place. 
Drugs prone to cause disorder of the kidney may include nonsteroidal anti-inflammatory 
drugs (NSAIDs), antibiotics (aminoglycosides, new quinolones), immunomodulatory agents, 
Stage Classification standard by SCr Classification standard by urine 
output
1 SCr more than 27 μmol/l (0.3 mg/dl) or SCr elevated to 1.5–1.9 times 
normal values
Less than 0.5 ml/kg/h within 
6–12 h
2 SCr 2–2.9 times normal values Less than 0.5 ml/kg/h in more 
than 12 h
3 SCr elevation to ≥3 times normal values or SCr ≥ 354 μmol/l (4.0 mg/dl) or 
start of renal replacement therapy
Anuria for 12 h
Table 3. KDIGO classification.
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contrasts (iodinated contrast), anticancer drugs (cisplatin), vitamin D and calcium prepara-
tions, and drugs for high blood pressure (RAAS blockade in particular) (Table 4).
2.3. Pathophysiological
The pathogenic mechanism of drug-induced AKI is poorly understood, but the following 
are known: the shift of hemodynamic status, the induction of acute interstitial nephritis, 
the induction of acute renal tubular injury, drug-induced thrombotic microangiopathy, the 
induction of glomerular nephritis, the induction by crystals in the tubular lumen, and others.
2.4. Kidney hemodynamic change
GFR, which is determined by glomerular pressure and filtration coefficients, is reduced by 
the inability to maintain glomerular pressure due to renal hemodynamic alterations, which 
are dependent on the renin-angiotensin aldosterone system (RAAS), endothelin system, 
prostaglandin system, and nitric oxide (NO). In addition, this condition occurs with minimal 
change in the vascular smooth muscle of the afferent renal arteriole and the efferent renal 
arteriole. Non-steroidal anti-inflammatory drugs (NSAIDs) are well-known offending agents 
and are associated with a high proportion of cases. Compared with internal medications, 
topical medicines have not been seen as a problem; however, recently, anti-inflammatory 
Classification Prospective drug
Renal hemodynamic alteration NSAIDs, renin-angiotensin system drugs, active vitamin D, calcineurin inhibitors 
(ciclosporin and tacrolimus), and diuretics
Thrombotic microangiopathy 
(TMA)
Angiogenesis inhibitors (VEGF inhibitors), gemcitabine, mitomycin C, interferon, 
mTOR inhibitors, thienopyridine (antiplatelet drugs), kinin, oxymorphone 
(opioid), oral contraceptives, and calcineurin inhibitors
Acute renal tubular injury General chemotherapy (cisplatin, ifosfamide, etc.), antibacterial drugs 
(aminoglycosides, amphotericin B, vancomycin, etc.), zoledronic acid, BRAF 
inhibitors, ALK inhibitors, iron chelators, heavy metals, and contrasts
Acute tubulointerstitial nephritis 
(AIN)
NSAIDs, antibacterial drugs (β-lactam, sulfa drugs, quinolones), diuretics, and PPI
Intratubular obstruction 
(crystalluria)
Crystal deposition-induced renal disease: antiviral drugs (cisplatin, ifosfamide, 
etc.), antibacterial drugs (sulfa drugs, ciprofloxacin), methotrexate, triamterene, 
ascorbic acid, sodium phosphate (laxative), warfarin
Glomerulonephritis Membranous nephropathy: NSAIDs, platinating agents, bucillamine, and 
penicillamine
MCD: NSAIDs, lithium, interferon, pamidronate, vaccines
FSGS: in addition to the above, hormonal agents and heroin
lupus nephritis: methyldopa, hydralazine, procainamide, and quinidine
Others liquorice root, vitamin D, and antithrombotic agents (Warfarin)
MCD, minimal change disease; FSGS, focal segmental glomerular sclerosis.
Table 4. Causes of drug-induced AKI.
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analgesic plasters containing NSAIDs that achieve comparatively higher blood levels have 
been sold; these forms of administration should also be considered. NSAIDs decrease blood 
flow in the afferent renal arteriole and GFR by blocking the production of prostaglandins. 
COX-2-selective inhibitors have turned out to be a cause of AKI development as well as 
COX-2-nonselective inhibitors, so attention should be paid to these inhibitors regardless of 
their mechanisms. In addition, RASS inhibitors cause the efferent renal arteriole to dilate and 
decrease GFR. These drugs have a protective effect for the kidney in CKD patients in the 
mid- and long term; however, our attention to AKI is required under circumstances where it 
is easy to reduce renal blood flow.
2.5. Causes of drug-induced thrombotic microangiopathy (drug-induced TMA)
TMA describes a disorder that is thought to be an aftereffect of pathological microvascular 
endothelial damage and has the three following features: hemolytic anemia, thrombocytope-
nia, and organ damage. Drugs may induce TMA in some instances, especially angiogenesis 
inhibitors such as vascular endothelial growth factor (VEGF) and anticancer drugs such as 
bevacizumab, which carry greater risks. It is thought that VEGF produced by glomerular 
podocytes is needed to maintain the function of endothelial cells and epidermal cells [7]. 
A high blood pressure and albuminuria are more problematic in drug-induced TMA; con-
versely, hemolytic anemia is less problematic. Aside from VEGF inhibitors, it is known that 
interferon and calcineurin inhibitors could increase drug-induced TMA that shows evidence 
of thrombocytopenia and schistocytes and signs in glomerular endothelial cells.
2.6. Causes of tubular damage
Drugs taken up by renal tubular epithelial cells mainly cause necrosis in the proximal tubule 
and apoptosis in the distal tubule and then cast formation in the tubular lumen and blockage 
by cells that fall behind into the renal tubule lumen, which consequently deteriorate quickly. 
The following drugs produce renal tubular injury and acute tubular necrosis (ATN) as symp-
toms progress: antineoplastic drugs such as cisplatin and ifosfamide, antibacterial drugs such 
as aminoglycosides, and antifungals such as amphotericin B. As a result of renal tubular injury, 
nephrogenic diabetes insipidus (NDI) and Fanconi syndrome are present. In the case of vanco-
mycin, the pathogenesis of kidney injury is thought to occur as a result of increasing oxidant 
stress [8] in the proximal kidney tubule, with casts appearing in the kidney tubule [9]. As risk 
factors, nephrotoxic drugs (aminoglycosides), in combination with high-dose diuretics (4 g/
day) and a high level of trough (≥20 μg/ml), patients in ICU for more than 1 week of treatment 
period is known. In addition, calcineurin inhibitors are recommended for therapeutic drug 
monitoring (TDM) for concentration-dependent development in the proximal kidney tubule.
2.7. Causes of acute interstitial nephritis
AIN involves drug-induced delayed hypersensitive reactions such as fever, rash, articular 
inflammation, or hepatic disorder in combination with declining kidney function, mainly 
involving neutrophil, T lymphocyte, and monocyte invasion in the renal stroma. However, 
these extrarenal manifestations are not inevitable and furthermore present with symptoms 
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of nephrosis with tiny variation at times. Drug-induced AIN occurs with a high frequency. 
Often, kidney injury occurs a few days to a few weeks after administration of the offending 
drug, especially antibacterial drugs, such as beta-lactam agents, quinolone agents, and rifam-
picin, which are all causes of AIN; however, the cases caused by NSAIDs and proton pump 
inhibitors (PPIs) have tended to increase. Immune checkpoint inhibitors (e.g., PD-1 inhibitor), 
such as nivolumab, which recently has rapidly been expanded to apply to numerous bacterial 
species, have been reported to increase kidney injury, including interstitial nephritis.
2.8. Tubule occlusion by crystals (crystal nephropathy)
The drug concentration in the renal tubule lumen increases in order to acidify urine by urinary 
concentration and excretion of H in the distal convoluted tubule. Under these acidic condi-
tions, crystallization of the drug occurs, inducing a nephropathy called crystal nephropathy. 
Antiviral drugs such as acyclovir and indinavir and methotrexate are known to cause kidney 
disorders due to drug-related crystal deposition in the renal tubules. There are many cases 
where casts are lost into the urine. Psychotropic agents and rhabdomyolysis-inducing drugs, 
such as statin medications or fibrates, are included in this category because obstruction of the 
renal tubule by myoglobin is possible. Excessive use of common supplements such as vitamin 
C carries a danger of promoting oxalic acid crystals.
2.9. Causes of glomerulonephritis-related damage
Glomerulonephritis induces functional disorder by blocking resorption in the renal tubule. 
The relation between rheumatoid arthritis agents, such as platinating agents or bucilla-
mine and membranous nephropathy and antihypertensive drugs, such as methyldopa or 
hydralazine and drug-induced lupus kidney inflammation, has been highlighted for some 
time. Interferon used in clinical application for the treatment of hepatitis, however, has been 
reported to induce minimal change disease (MCD) or focal segmental glomerular sclerosis 
(FSGS) [10]. In addition, a relationship between NSAIDs and membranous nephropathy or 
MCD has been indicated.
2.10. Contrast-induced nephropathy (CIN)
CIN is diagnosed in the case of kidney function declines after the administration of contrast in 
the absence of other causes (e.g., cholesterol embolus). The mechanism of CIN remains to be 
completely elucidated; however, the following factors have been considered: (1) a decrease in 
oxygen supply due to blood vessel spasm in the renal medulla, causing direct toxicity to the 
renal tubule, (2) a decreased renal perfusion by increased adenosine and endothelin or reduced 
carbon monoxide [11]; coexisting risk factors such as kidney function disorder, advanced 
age (more than 75 years old), dehydration, cardiac failure, agents (diuretic agents, NSAIDs, 
aminoglycoside antibiotics, and vancomycin), diabetes mellitus, and multiple myeloma; in 
particular, kidney function disorder is the greatest risk factor. In addition, diabetes mellitus, 
which has become recognized as a risk factor, is considered a factor in itself and promotes 
a further elevated risk for the development of CIN in CKD patients through its complica-
tions. Gadolinium (Gd) contrast agents, including extracellular liquid Gd contrast agents and 
hepatocyte-specific Gd contrast agents, are classified as linear and macrocyclic or as ionic and 
Advances in Nephropathy178
nonionic on the basis of their chelate structure. Gd is a heavy metal element and is highly 
poisonous in the case of direct administration. Therefore, Gd is administered as a chelate so 
that it is excreted into the urinary tract (and partly into the biliary tract) without metaboliz-
ing inside the body. Adverse events of Gd contrast agents occur in three types: acute adverse 
effect, occurring within 1 h after intravenous injection; delayed adverse effect, occurring from 
1 h to 1 week after intravenous injection; and super-delayed adverse effect, such as nephro-
genic systemic fibrosis (NSF), which occurs more than 1 week or even several years after intra-
venous injection. Moreover, there is a newly recognized problem that Gd remains in the brain 
without causing kidney disorder [12]. Many subsequent studies have reported that residual 
Gd in the body is more linear type than macrocyclic type [13, 14] and remains not only in the 
brain but also throughout the whole body when the residual volume is increased in the pres-
ence of kidney disorder [15]. Complications caused by residual Gd have not been reported; 
however, patients who are frequently exposed to contrast generally have some kind of chronic 
disease, so the effects of residual Gd may be obscured or misinterpreted as subjective or objec-
tive evidence of their disease. Notably, in the case of Gd remaining in the brain, Gd deposits 
in neuronal nuclei have been observed by electronic microscopy [16]. Gd is not liberated very 
well; its thermodynamic stability constant and condition stability constant are high, leading to 
a high chelate stability. Its half-life at pH = 1.0 represents the time required to liberate half of 
Gd from the chelate under pH = 1.0, but it remains stable much longer under other conditions. 
In general, linear type chelates have a lower stability than macrocyclic chelates [17].
2.11. Other etiologies
There are cases that result from electrolyte abnormalities; for example, the abnormal use of 
diuretic drugs or glycyrrhiza causes kidney disorder by hypokalemia and excess administra-
tion of vitamin D preparation causes kidney disorder via hypercalcemia. In addition, warfa-
rin, which has been in use as an anticlotting drug for many years, has been reported to easily 
cause kidney disorders, particularly when PT-INR exceeds 3; however, the mechanism has 
yet to be determined [18]. Among the pathological findings of kidney disorder due to warfa-
rin, red blood cell casts have been observed with high frequency.
2.12. Clinical presentation of drug-induced AKI
Symptoms appear within a few hours or a few years after taking or using the offending agents, 
and in some cases, no symptoms appear. Renal tubular injury sometimes presents with the 
following symptoms: polyuria, urinary frequency, thirst, fatigue, and anorexia. Skin rash, 
joint pain, fever, and hematuria are observed as signs of allergy. In the case of thrombotic 
microangiopathy, purple spots and bleeding tendency with thrombopenia appear in the soft 
palate and the extremities. In the presence of crystal nephropathy, knock pain is commonly 
observed dorsally and bilaterally with postrenal acute renal failure. With progression, acute 
or chronic renal failure develops.
2.13. Diagnosis of drug-induced AKI
The size of the kidney is normal or swollen. The elevation of urinary N-acetyl-β-glucosaminidase 
(NAG) or L-type fatty acid binding protein (L-FABP) is observed with a urine test. In particular, 
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the proteinuria is of low grade (less than 1 g/day) and associated with renal tubule dysfunction 
(mainly β2-microglobulin). However, the urinary findings depend on the presence or absence of glomerular lesions. The detection of urinary eosinophils has been used for the diagnosis of 
drug-induced AKI [19], but is weak evidence for clinical judgment, as it has a lower positive-
predictive rate and a higher false-negative rate than other markers. Renal hemodynamic type 
is rarely examined, but hyperkalemia is presented in patients receiving drugs related to the 
RAA system. Thrombotic microangiopathy is commonly associated with thrombocytopenia, 
an appearance of schistocytes, and elevation of lactate dehydrogenase (LDH). In acute tubular 
necrosis, muddy brown casts are observed in the urinary sediment. The examination of accu-
mulation enhancement in the kidney by gallium scintigraphy is used for the diagnosis of acute 
interstitial nephritis related to antibacterial drug overdose, but this is not a common diagnostic 
approach because it is difficult to distinguish between drug accumulation and infection or glo-
merular disease. Then, there is the problem of the low specificity of the drug-induced lympho-
cyte stimulation test (DLST), which is used to examine the patient’s blood in cases of suspected 
drug-related AKI. In crystal nephropathies, urinary crystals or high-brightness echo on renal 
ultrasonography due to crystals may be observed. Renal biopsy is not essential for diagnosing 
drug-induced AKI, and it is considered to produce a hangover of kidney disorder after drug 
withdrawal or maintain uric protein in the nephrotic range and glomerular hematuria.
2.14. Treatment of drug-induced AKI
The treatment is essentially discontinuing use of the suspected drugs; treatment also includes 
proper maintenance of body fluid volume and blood pressure, and sometimes, the use of 
rehydration or diuretics to maintain adequate perfusion of the kidney. We consider using 
kidney replacement therapy in cases where the following symptoms are observed: a marked 
elevation of BUN or hyperkalemia, pulmonary edema that fails to respond to diuretics, or 
uremic symptoms. In the treatment of drug-induced acute interstitial nephritis, we may con-
sider steroid therapy after early withdrawal of drugs (within 2 weeks), when kidney disorder 
hangover occurs under the discontinuation of the suspected drug [20]. We use upward of 
1 mg/kg/day steroid for a short period, but there are no large-scale studies related to patient 
characteristics or symptoms that indicate this therapy. In addition, alkalinization of the urine 
with baking soda or acetazolamide treatment is used to promote the solubility of crystals in 
the case of kidney disorder caused by the deposition of methotrexate crystals in the renal 
tubules. Methotrexate has a low molecular weight of 454.44, its protein binding rate is 50%, 
and it is removed rapidly from plasma; because of these factors, a combination of plasma 
exchange and hemodialysis with a high-flux membrane is effective. A recombinant enzyme 
preparation that directly decomposes methotrexate has already been developed in Europe 
and the United States. Contrast nephropathy rarely needs specific treatment to resolve. With 
a lower residual renal function or oliguria, treatment is needed for advanced CKD. It is said 
that the aggressive introduction of blood purification therapy as well as other AKI avoidance 
is helpful to reduce case fatality rate and complications such as progression of kidney disor-
der. Treatments such as diuretics, human atrial natriuretic peptide, and low-dose dopamine 
have been considered by now, but these treatments are not recommended, as their usefulness 
has not yet been demonstrated. Thus, it is necessary to consider fluid therapy after CIN and 
important to carefully select the infusion volume after evaluating body fluid volume because 
an excessive increase in fluid could elevate the case fatality rate.
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3. Nondrug-induced AKI
3.1. Heart function and AKI
There are many important factors related to both the heart and the kidney that indicate the 
following pathway leading to kidney disorder or cardiac arrest (Figure 1) [21]. Patients who 
have suffered acute decompensated heart failure tend to develop AKI during the course of 
treatment, which is known to worsen renal function despite the correction of heart function 
[22, 23]. Kidney function disorder results in heart function disorder, and this connection has 
recently been referred to as cardiorenal syndrome (CRS). Ronco et al. classified clinical condi-
tions into five groups, divided by acute and chronic [24]. In this classification, we give an 
outline of types CRS1 and CRS3, related to heart function and AKI.
3.2. Hepatorenal syndrome
3.2.1. Pathogenesis of hepatorenal syndrome
The arterial vasodilation theory is universally recognized as underlying hepatorenal syn-
drome [25]. With progression, hepatic cirrhosis and vascular resistance are reduced, and 
blood pressure is decreased by vasodepressor factors such as carbon monoxide and can-
nabinoids [26]. At the early stage of hepatic cirrhosis, compensatory mechanisms such as 
the elevation of cardiac pumping, the enhancement of renin-angiotensin system, and the 
expression of sympathetic nervous system or vasopressin work to balance the change, so 
Figure 1. Correlation between heart function disorder and kidney function disorder.
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blood pressure increases. However, with further progression of hepatic cirrhosis, the so-
called cirrhosis cardiomyopathy occurs, and cardiac output is reduced by the reduction 
of myocardial extension ability and abnormality in the impulse conducting system [27]. In 
addition, cirrhosis is often associated with the development of comparative adrenal failure 
and has the tendency to reduce the blood pressure. To compensate, the renin-angiotensin 
system and the secretion of vasopressin are further increased [28]. Disorders in which free 
water cannot be drained from the kidney tubule or sodium retention is elevated cause sym-
pathetic hyperactivity; as a result, circulating plasma volume cannot be reduced, leading 
to excess fluid accumulation as ascitic fluid or edema and hyponatremia [29]. In addition, 
sympathetic hyperactivity and vasopressin are vasoconstrictive, and renal blood flow is 
additionally reduced [25]. In other words, compensation, which was useful to maintain 
body blood pressure in the early onset of hepatic cirrhosis, reduces renal blood flow and 
leads to auto-regulation breakdown, inasmuch as it reduces glomerular filtration. Moreover, 
in cases of hepatic cirrhosis, even where there are no obvious infectious diseases, inflamma-
tory cytokines, such as IL-6 or TNF-α, are elevated, and an impact for portal hypertension 
and circulation dynamics is considered [30].
3.2.2. Classification of clinical entity in hepatorenal syndrome
In general, hepatorenal syndrome, pathophysiologically, is broadly separated into two cat-
egories by the speed of progress of kidney function disorder. Quick progression (type 1) is 
defined as a serum creatinine level that is elevated more than two times within 2 weeks and 
elevated to more than 2.5 mg/dl; cases that progress more slowly are type 2. Part of the reason 
for classifying in this way is that type 1 is associated with singularly poor prognosis. The 
3-month mortality rate of type 1 is almost 70%, while that of type 2 is approximately 10%, and 
it is reported that the median survival time after the onset of type 1 is approximately 2 weeks 
[31]. Some cases of type 1 involve a natural outbreak that develops into infections, such as 
spontaneous bacterial peritonitis, pneumonia, and opportunistic urinary tract infections 
[32, 33]. Therefore, early diagnosis and therapeutic intervention are desirable in type 1.
3.2.3. Diagnosis of hepatorenal syndrome
For diagnosis, the criterion of hepatorenal syndrome that has been traditionally propounded 
indicates that serum creatinine levels are elevated to more than 1.5 mg/dl [34]. That is, the 
condition requires that the serum creatinine level was more than 1.5 mg/dl in hepatorenal 
syndrome, regardless of the baseline level of hepatorenal syndrome or elevation degree and 
speed. This was viewed with suspicion in distinguishing AKI from CKD [35]. Then, ICA pro-
posed a partial change of the diagnostic criteria for KDIGO, as AKI in hepatorenal syndrome 
patients, under the guidelines for AKI, which were announced by KDIGO and universally 
recognized. The difference in diagnostic criteria between ICA and KDIGO is the urinary out-
put cut-off. The reason is that regardless of the relative maintenance of GFR, compared to 
other AKI, the potential for oliguria in hepatic cirrhosis patients is not negligible [11]. The 
ICA proposed to set the serum creatinine level within 3 months before admission as baseline, 
unless serum creatinine had been measured within the previous 7 days [35].
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3.3. External injury and AKI
We give an outline of rhabdomyolysis (crush syndrome) in order to understand AKI due to 
external injury. Crush syndrome is a generalized diagnosis of the symptoms caused by skel-
etal muscle damage by external or other mechanical injury. First, regional edema occurs in the 
damaged skeletal muscle of the extremity, so that intravascular volume is reduced. Because the 
extremity compartment is restricted in space, the inner pressure of the compartment increases 
exponentially, and this in turn reduces arterial perfusion to the muscle. On the grounds that 
perfusion pressure is defined by the mean arterial blood pressure and compartment inner 
pressure, the perfusion pressure is conspicuously reduced under these circumstances, which 
means arterial blood pressure is low and compartment inner pressure is high. Skeletal muscle 
cells are destroyed by direct external or ischemic injury, and the intracellular components, 
including myoglobin, potassium, and urinary acid, are released and circulate at the time of 
reperfusion [36]. The mechanism of AKI by rhabdomyolysis remains to be explained; however, 
it is thought that it concerns the constriction of renal blood vessels directly, or ischemic renal 
tubular injury and tubular obstruction. Many different mechanisms have been related to the 
renovascular contraction characteristic of AKI by rhabdomyolysis. First, intravascular volume 
reduces in order to move fluid for the damaged skeletal muscle, and the renin-angiotensin 
system, vasopressin, or sympathetic nervous system cause hyperactivity, so kidney blood ves-
sels contract. Next, increased levels of vascular mediators such as endothelin-1, thromboxane 
A2, TNF-α, and F2-isoprostane are additionally vasoconstrictive. Conversely, vasoactive nitric 
oxide (NO) is used to remove myoglobin such that a deficiency develops and renal blood flow 
becomes further diminished. Finally, a direct disorder caused by inflammation or oxidation 
with vascular endothelial disorder exacerbates these vascular mediators at the same time [37]. 
AKI by crush syndrome is also linked to the possibility of the same kidney disorder mecha-
nism that occurs in tumor lysis syndrome, in addition to the mechanism of AKI by rhabdomy-
olysis described earlier, that is, a large amount of urinary acid being released from the injured 
skeletal muscle [38]. AKI by crush syndrome is more associated with the development of fluid 
overload, life-threatening acidosis, and hyperkalemia than AKI of other causes. Notably, an 
abrupt increase in potassium level, even if it remains within normal range, is an indication 
for dialysis [39, 40]. The dialysis initiation standards for AKI, especially dialysis initiation in 
an early period, remain greatly debated even though a large-scale trial has been conducted in 
recent years [41]. The evidence supporting renal replacement therapy for AKI caused by crush 
syndrome is limited and thus remains inconclusive. However, given that the high dialysis 
enforcement rate and clinical indications for fundamental therapy itself do not exist, early 
introduction may be useful [42]. Nevertheless, we should consider not only renal replacement 
therapy intended for the removal of myoglobin but also early introduction as for AKI [43].
3.4. Sepsis-associated AKI: SA-AKI
3.4.1. Mechanism of development and pathophysiology in SA-AKI
An “inflammation” mechanism is responsible for a large part of the occurrence of SA-AKI. When 
excessive inflammation is induced, organ damage is caused by hypercytokinemia, called a 
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cytokine storm. For example, in endotoxemia caused by Gram-negative bacteria infection, 
the signal is released via Toll-like receptor (TLR) 4, mediators such as cytokines are released 
via the MyD88-dependent pathway or TRIF-dependent pathway, and factors promoting 
adherence to vascular endothelium are produced. Furthermore, in the glomerulus, expand-
ing of the efferent arteriole, changes in tubuloglomerular feedback, and intumescence of the 
vascular endothelia are induced and result in a reduction of GFR. Furthermore, impaired 
renal tubular reabsorption of solutes or anaerobic metabolism by mitochondria occurs, and 
renal tubular dysfunction is caused by hypoxia of the medulla renalis [44]. However, in mice 
deficient in TLR4, which recognizes the endotoxin, and administered LPS organ-protection, 
action was not exhibited. In mice deficient in MyD88, which lies downstream of TLR4 [45], or 
TLR9, which recognizes bacterial DNA, AKI was alleviated [46]. This phenomenon can also 
be induced by other Gram-positive bacteria or viruses. Furthermore, when Bellomo et al. [47] 
measured renal blood flow in a sheep model with continuous infusion of bacteria, during 
hyperdynamic shock, which dilates peripheral blood vessels and increases cardiac output, 
renal blood flow increased, but glomerular filtration rate decreased. The cause was thought 
to be that the afferent arteriole dilated but the efferent arteriolar dilated without constric-
tion. Progress of clinical condition additionally induces microvascular injury, which in turn 
induces afferent arteriole constriction and results in the persistent loss of glomerular filtration.
3.4.2. Risk factors
Risk factors of abnormal balance of tonus in the afferent/efferent, which is recognized in 
SA-AKI, include older age, preexisting chronic kidney disease (CKD) or cardiovascular con-
dition, severe arteriosclerosis (hypertension, diabetes mellitus), and drug use (especially Ras 
inhibitors or NSAIDs).
3.4.3. Targeted therapy
Even though life-saving guidelines for sepsis treatment were proposed and practically applied, 
the incidence and severity of SA-AKI have not been alleviated [48]. The immediate action for 
patients with AKI is emergency response associated with severe kidney injury represented 
by severe uremia, hyperkalemia, volume overload (renal failure), or metabolic acidosis. When 
sepsis occurs, because of the relative lack of volume flow through the circulation, correcting 
volume flow through the circulation and maintaining perfusion rate of the kidney early are 
important. On the other hand, because excessive volume administration cannot improve cir-
culatory dynamics and may worsen prognosis, vasoconstricting drugs should be administered 
after correcting volume flow through the circulation. With regard to the quality of transfusion, 
because artificial colloid solutions such as HES may cause further kidney injury in patients 
requiring renal replacement therapy (RRT) compared to extracellular fluids such as saline, their 
use should be avoided (VISEP study 2008, 6S trial 2012, CHEST study 2012). In the case that 
hyperdynamic shock occurs, to maintain organ perfusion pressure more than 65 mmHg, a 
vasoconstrictor drug (noradrenaline: NA) [49] is recommended as the first-line therapy, and 
vasopressin (VSP) is recommended as the second-line therapy. Furthermore, the focus of infec-
tion should be managed by drainage and so on. Antibacterial drugs should be administered 
as soon as possible, and if possible, injection with broad-spectrum antibiotics should be per-
formed within an hour. At this time, antibiotics should be selected considering renal prognosis.
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4. Prognosis of AKI
Studies on the long-term prognosis of AKI have advanced rapidly since approximately 2010 
[50–62]. Consequently, advances in the understanding about the association between AKI and 
cardiovascular disturbance have been seen. The absence of consensus on the definition of 
recovery from AKI was previously considered problematic [63], and this problem was high-
lighted again by Sawhney’s systematic review [61]. After this systematic review, two large 
studies, which were likely to be underpinnings of the consensus on the definition of recovery 
from AKI, were published [64, 65]. Accordingly, the importance of considering the time from 
the peak of SCr value to recovery and the importance of considering rehospitalization after 
recovery from AKI were suggested in order to define recovery from AKI. Although AKI or 
recovery from AKI was defined by SCr in all the above studies, it is impossible to capture 
changes in the tissues not reflected in kidney function because SCr value is the index of kidney 
function, and it is possible that changes in the kidney reflected in urine biomarkers have an 
impact on the long-term prognosis of AKI, even if there is no rise of SCr suggested, according 
to the article of the TRIBE-AKI study team [66]. It is necessary to think about what we can do 
for patients with AKI, and in the Japanese guidelines, it is recommended to assess the presence 
of a transition from AKI to CKD according to KDIGO guidelines. However, giving a referral 
for follow-up to patients targeted with clinical stratification stage 2 or stage 3, an outpatient 
department of a facility in Canada suggested, is because doing for patients with AKI includes 
those at clinical stratification stage 1 (in particular, the rise of SCr 0.3 mg/dl) is not realistic [67]. 
In actuality, in data from a US veteran’s hospital in 2012, the rate of referral, even for patients 
at clinical stratification stage 2 or 3, to the department of internal nephrology medicine after 
discharge from a hospital is approximately 20%, and room for improvement was suggested 
[68]. Among patients with AKI receiving acute renal replacement therapy, there is evidence to 
suggest that there is a decreased mortality rate for patients who receive follow-up from a kid-
ney physician [69]; it is possible that this outcome is attributable to the careful management by 
doctors whose reasons have not been considered. There is also an example of outcomes being 
improved when patients visit a doctor who conducts daily practice, even without a follow-up 
by a kidney physician [70]. There are data from the US that hospital physicians did not fully 
inform outpatient doctors during hospitalization for AKI onset [71]. It may be the role of the 
doctor who diagnosed AKI to inform the outpatient clinician of the risk of CKD onset and 
progression and avoiding prescription of drugs with renal toxicity after AKI.
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